New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer

Share this content:
More than 400 thousand bone scintigraphy studies were performed for Medicare patients in 2014.
More than 400 thousand bone scintigraphy studies were performed for Medicare patients in 2014.

A working group of several clinical societies developed appropriate use criteria for the use of bone scintigraphy in the diagnosis and management of prostate and breast cancer. The guidelines were published in the Journal of Nuclear Medicine.

Highly sensitive and readily available imaging can lead to inappropriate use with associated unnecessary exposure to ionizing radiation and increased health-care costs. Bone scintigraphy is a high volume procedure with more than 400,000 studies performed for Medicare patients in 2014. Further, bone scintigraphy is commonly used in the setting of breast and prostate cancer diagnosis and treatment.  

The appropriate use criteria were developed in collaboration with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM), and the American Society of Clinical Oncology (ASCO). The group developed a list of clinical scenarios and contraindications for the use of bone scintigraphy in the diagnosis and management of breast and prostate cancer. Likewise, the Pacific Northwest Evidence-Based Practice Center of Oregon Health and Science University conducted a systematic review of the literature to help inform the workgroup.

Key recommendations for the use of bone scintigraphy in patients with prostate cancer include initial staging in patients with intermediate-risk and high-risk prostate cancer. The recommendations also indicate that bone scintigraphy is usually appropriate in patients with bone-related symptoms at any stage, patients with a pathologic fracture, and patients undergoing radionuclide bone treatment.  

Key recommendations for use of bone scintigraphy in patients with breast cancer include initial staging in patients with positive nodes, bone related symptoms at any stage, and those undergoing radionuclide bone treatment.

“It is felt that by combining multispecialty expert opinion with the existing literature, the most accurate assessment possible can be made for the clinical utility of bone scintigraphy,” the authors wrote.

“The lack of published evidence for the use of bone scintigraphy in specific clinical scenarios has not yet had a dramatic effect on relative reimbursement for this important test; however, as new regulations take effect requiring referring physicians to consult clinical decision support tools before ordering bone scintigraphy, access to this important technology may become severely limited unless [appropriate use criteria] are written for inclusion of this test as an option in clinical decision support tools,” the authors stated.

Reference

1. Donohoe KJ, Cohen EJ, Giammarile F, et al. Appropriate use criteria for bone scintigraphy in prostate and breast cancer: summary and excerpts. J Nucl Med. 2017;58(4):14N-17N.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs